{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-24-000059","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.775314+00:00","generated_at":"2026-06-01T05:17:02.407571+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Skye Bioscience Phase 2a trial of SBI-100 OE fails primary endpoint; discontinues ophthalmology program","bullets":["Phase 2a trial of SBI-100 in 56 patients with POAG or OHT did not meet primary IOP endpoint vs placebo.","Drug safe; all patients completed study with no early discontinuations due to adverse events.","Company discontinues all SBI-100 development and ophthalmology pipeline; focuses on obesity program with Nimacimab.","Phase 2 obesity trial of Nimacimab expected to start Q3 2024; cash runway extended into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-24-000059","json":"https://secwatch.observer/filing/0001516551-24-000059.json","markdown":"https://secwatch.observer/filing/0001516551-24-000059.md","text":"https://secwatch.observer/filing/0001516551-24-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000059/0001516551-24-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000059/skye-20240610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:17:02.407571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}